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Abstract: Biomaterials-based three-dimensional scaffolds are being extensively investigated 
in bone tissue engineering. A potential scaffold should be osteoconductive, osteoinductive, and 
osteogenic for enhanced bone formation. In this study, a three-dimensional porous polycapro-
lactone (PCL) scaffold was engineered for prolonged release of resveratrol. Resveratrol-loaded 
albumin nanoparticles (RNP) were synthesized and entrapped into a PCL scaffold to form 
PCL-RNP by a solvent casting and leaching method. An X-ray diffraction study of RNP and 
PCL-RNP showed that resveratrol underwent amorphization, which is highly desired in drug 
delivery. Furthermore, Fourier transform infrared spectroscopy indicates that resveratrol was 
not chemically modified during the entrapment process. Release of resveratrol from PCL-RNP 
was sustained, with a cumulative release of 64% at the end of day 12. The scaffold was evaluated 
for its bone-forming potential in vitro using human bone marrow-derived mesenchymal stem 
cells for 16 days. Alkaline phosphatase activity assayed on days 8 and 12 showed a significant 
increase in activity (1.6-fold and 1.4-fold, respectively) induced by PCL-RNP compared with 
the PCL scaffold (the positive control). Moreover, von Kossa staining for calcium deposits on 
day 16 showed increased mineralization in PCL-RNP. These results suggest PCL-RNP signifi-
cantly improves mineralization due to its controlled and prolonged release of resveratrol, thereby 
increasing the therapeutic potential in bone tissue engineering.
Keywords: therapeutic scaffolds, polycaprolactone scaffolds, bone tissue engineering, resvera-
trol, albumin nanoparticles, mesenchymal stem cells
Introduction
Regeneration of closed and compound fractures of bone tissue with bone loss of more 
than 3 cm is a complex process. In comminuted and segmental fractures having bone 
loss of more than 6 cm, the chances of deformity, shortening of bones, and recurrent 
fractures due to nonunion, malunion, or cross-union after healing are   common.1–3 
Treatment for bone fractures measuring more than 3 cm includes autograft, allograft, 
xenograft, and transplant with permanent synthetic materials.1 Autologous transplanta-
tion of a bone graft from the iliac crest is considered the “gold standard” for treatment 
of complex fractures.4 However, such traumatic harvesting of bones is associated 
with risks of morbidity due to nerve injury, causing numbness, difficulty in walking, 
decreased sexual activity, and persistent back pain.5 Allografts and xenografts have 
proven to be inferior to autografts and are associated with risks of graft rejection, 
disease transmission, and nonunion of grafts at the fracture site,1,4 whereas transplant 
of permanent synthetic materials induces osteolysis and an inflammatory response. 
To overcome the complexity of bone loss and morbidity, three-dimensional scaffolds International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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made of biomaterials are being extensively studied. Three-
dimensional scaffolds can increase orientation of cells and 
provide solid support for cells in the margin of fractured 
bone to attach and grow into the fractured space, thereby 
decreasing the risk of malunion or cross-union. Also, three-
dimensional scaffolds fortified with nanohydroxyapatite and 
bioglass ceramics increase mechanical strength, in addition 
to having osteoconductive properties,6 whereas metallic 
nanoparticles, such as silver, zinc, and copper, increase 
the antimicrobial activity of these scaffolds.7 Further, the 
scaffolds should also possess properties to enhance cell 
attachment and proliferation, to facilitate angiogenesis, 
and to increase calcium deposition when inserted into the 
fractured site.6 In brief, treatment of complex bone fractures 
with three-dimensional scaffolds is promising, provided that 
scaffolds are osteoconductive and osteoinductive, and are 
able to facilitate osteogenesis.
Clinically, sustained release of recombinant human bone 
morphogenic protein-2 for bone formation revealed severe 
complications, including swelling in the throat and neck, 
radiculitis, obstruction of the airways due to local swelling, 
swelling in the tissues and organs surrounding the site of 
release of recombinant human bone morphogenic protein-2, 
and an increased incidence of cancer and male sterility.8–11 
Since factors like bone morphogenic proteins, basic fibroblast 
growth factor, and transforming growth factor beta are a class 
of indigenous growth factors which signal numerous pathways 
in the human system, release of these factors at a therapeutic 
site could produce undesirable side effects in surrounding 
tissues, apart from bone regeneration. Also due to continuous 
release of these factors, they could be absorbed into the blood 
stream and produce systemic effects. Therefore, therapeutic 
use of indigenous growth factors for a prolonged time is not 
desirable. Ideally, a bioactive molecule used for therapeutic 
enhancement in tissue engineering should not cause any unde-
sirable effects in the human system. Bioactive small molecules 
of plant origin with the potential to induce osteogenesis and 
not eliciting any unfavorable events in the human system could 
be released at the site of bone regeneration. 
Resveratrol is a polyphenolic phytoestrogenic com-
pound obtained from plants. It has been extensively studied 
for its anticancer activity, antiaging activity, and potential 
antioxidant properties, apart from its osteogenic potential. 
Resveratrol is widely used as an antioxidant supplement, 
and its long-term use has not been reported to have adverse 
effects on the human system. Hence, therapeutic targeting of 
resveratrol in micromolar concentrations is safe and effective 
for bone tissue engineering. Sustained release of resveratrol 
by entrapping resveratrol-loaded albumin nanoparticles 
(RNP) into scaffolds increases the therapeutic potential of 
the scaffold in bone tissue engineering. A previous study 
reported that sustained release of resveratrol from nanofi-
bers increases alkaline phosphatase and calcium deposits 
in vitro.12 In brief, treatment of complex bone fractures with 
three-dimensional scaffolds is promising, provided scaf-
folds are osteoconductive and osteoinductive, and are able 
to facilitate osteogenesis.
Resveratrol is a well studied polyphenolic phytoestro-
gen that promotes proliferation and differentiation of bone 
marrow-derived mesenchymal stem cells into osteoblasts.8 
Resveratrol increases alkaline phosphate activity, enhanc-
ing differentiation of bone marrow-derived mesenchymal 
stem cells to an osteoblast lineage.12–14 Resveratrol also 
increases proliferation and differentiation of osteoblasts, thus 
increasing the propensity for bone formation.15 Although 
resveratrol has the potential to enhance bone formation, it is 
rapidly metabolized and excreted from the body as sulfated 
and monoglucuronide derivatives.16,17 Controlled release of 
resveratrol at the site of bone loss could be more efficient 
than oral administration. Hence a three-dimensional porous 
polycaprolactone (PCL) scaffold was fortified with RNP to 
release resveratrol in a controlled manner, thereby overcom-
ing the effects of rapid resveratrol clearance from the body. 
PCL is a synthetic polymer that has been widely investigated 
in tissue engineering and drug targeting. The bioabsorbability, 
biocompatibility, and mechanical strength of PCL makes it 
well suited for bone tissue engineering.12
Bone regeneration could be accelerated by supplementing 
scaffolds with bioactive molecules that increase proliferation 
and differentiation of mesenchymal stem cells into osteoblasts 
and promote osteoblast proliferation and calcium   deposition. 
Based on this hypothesis, we developed PCL-RNP and 
evaluated its bone-forming potential and drug release kinet-
ics in vitro. Morphologic analyses of PCL-RNP scaffolds 
were done by scanning electron microscopy and qualitative 
analysis by Fourier transform infrared (FTIR) spectroscopy 
and X-ray diffraction. Further, physical characterization of 
RNP was carried out using scanning electron microscopy, 
atomic force microscopy, and a zetasizer. The mineralization 
potential of PCL-RNP was evaluated in vitro using human 
bone marrow-derived mesenchymal stem cells (hBMSCs) 
wherein an alkaline phosphatase assay showed increased 
activity in PCL-RNP compared with a PCL scaffold (the 
positive control). Moreover, PCL-RNP potentially increased International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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mineralization compared with PCL (negative and positive 
controls), which was confirmed with von Kossa staining for 
calcium deposition. The results obtained suggest enhancement 
of the therapeutic potential of PCL-RNP in vitro as a result 
of sustained and prolonged release of resveratrol.
Materials and methods
Bone marrow cells were harvested in accordance with eth-
ics committee requirements by obtaining written informed 
consent from patients undergoing experimental cell therapy 
for spinal injury. The protocol for sample collection was 
reviewed and accepted by the ethics committee of Life Line 
Rigid Hospital, Chennai, India.
Preparation of rNPs
RNPs were prepared by a coacervation process described 
elsewhere.18 Briefly, albumin (2% w/v) was dissolved in 
deionized water and the pH was adjusted to 7. Resveratrol 
10 mg was dissolved in 200 µL of ethanol and added drop-
wise to the albumin solution and incubated for one hour in 
the dark at room temperature. Ethanol was added dropwise 
at a flow rate of 1 mL per minute under constant stirring until 
the solution became turbid. Next, 8% glutaraldehyde was 
added to harden the coacervates. The mixture was stirred 
constantly for 2 hours to crosslink the proteins. The nano-
particles formed were centrifuged at 18,000 rpm and 4°C 
for 30 minutes. The supernatant was stored for estimation of 
unbound resveratrol. The pellet was suspended in phosphate-
buffered saline (pH 7.4), centrifuged at 18,000 rpm and 4°C 
for 30 minutes, resuspended in phosphate-buffered saline, 
and lyophilized. The entrapment efficiency (E) of the process 
was calculated using the formula
  E = [(TRes – FRes)/TRes] × 100%
where TRes is the total amount of resveratrol added and FRes 
is the free drug in the supernatant.
Preparation of scaffolds
PCL (molecular weight 80,000, purchased from Sigma-
Aldrich, Bangalore, India) scaffold was prepared by a surface 
leaching method.19 Polycaprolactone (10% w/v) was dissolved 
in an equal solvent mixture of dichloromethane and ethanol 
followed by addition of RNP (10% w/w) to form PCL-RNP 
under constant stirring for 30 minutes. The mixture was then 
sonicated for 5 minutes on ice, and finely ground sucrose 
(particle size 100–200 µm) was added in a ratio of 1:5 (PCL 
to sucrose), stirred to create a uniform slurry, and cast into 
glass molds. These plates were dried at room temperature fol-
lowed by leaching of sucrose from the scaffold in deionized 
water to form a porous structure. The porous scaffold was 
treated with 0.5 M NaOH for 4 hours to impart hydrophilicity 
and washed thoroughly with ethanol and phosphate-buffered 
saline under sterile conditions until the pH of the scaffold 
became neutral. PCL scaffolds prepared as described earlier 
without addition of RNP served as the control.
characterization of materials
scanning electron microscopy
The scaffolds were characterized by field emission scanning 
electron microscopy under low vacuum mode (60 Pa) with a 
low field detector and an applied voltage of 5 kV . The scaf-
folds were cut using a sharp razor to 1 cm × 1 cm dimensions 
and placed on aluminum foil for scanning.
FTIr
The synthesized scaffolds were examined by FTIR using an 
Alpha FTIR spectrophotometer (Bruker Optics, Mumbai, 
India). First, 3 mg of the sample was mixed with 300 mg of 
potassium bromide (KBr) and made into pellet under vacuum. 
The pellet was then analyzed in the range of 4,000–500 cm−1 
with a resolution of 1 cm−1.
X-ray diffraction
The powdered scaffold was subjected to X-ray diffrac-
tion using the X’Pert-PRO (PANalytical, Almelo, The 
  Netherlands) which operates at 40 kV with a current of 
30 mA and uses kα radiation (1.544 A). The 2θ scan range 
was fixed at 5°–80° with a step angle of 0.0170.
characterization of rNPs
Atomic force microscopy was performed using a 1500 scan-
ning probe microscope (Agilent Technologies, Santa   Barbara, 
CA, USA). A suspension containing the nanoparticles was 
diluted 1:100 times in water and coated on silicon tape in a 
spin coat unit under vacuum. Scanning of the particles was 
carried out in noncontact (ACAFM) mode with a scan speed 
of 3.007 lines per second; the cantilever force and frequency 
were 4% and 310.6 kHz, respectively.
Particle size, polydispersity index, and zeta potential 
were measured using a Mastersizer (Malvern Instruments, 
Malvern, UK). The average particle size was less than 
200 nm and the polydispersity index was below 0.2, both of 
which were considered to be good, and the zeta potential was 
around ±30 mV and also considered to be acceptable.International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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analysis of resveratrol release  
from scaffolds
Preweighed 1.5 × 1.5 cm scaffolds were incubated in 2 mL 
of phosphate-buffered saline under static conditions. At pre-
determined time intervals, 300 µL was removed by replacing 
equal amounts of phosphate-buffered saline. The absorbance 
of resveratrol released was read at 303 nm using an enzyme-
linked immunosorbent assay reader. The concentration of 
resveratrol released was then obtained from the standard curve 
for resveratrol. The percentage release was calculated from the 
initial amount of nanoparticles entrapped per scaffold.
collection of human bone marrow
A bone marrow sample (20 mL) was aspirated from the iliac 
crest region of three subjects aged 35–45 years and having 
a mean body mass index of 24.7 ± 2.6 kg/m2. All samples 
were immediately processed to separate hBMSCs from the 
aspirated marrow.
Isolation and culture of hBMscs
Mononuclear cells were obtained by density gradient cen-
trifugation of bone marrow aspirates using Ficoll-PaqueTM 
(GE Healthcare Life Sciences, Piscataway, NJ, USA).20 
The mononuclear cell layer was carefully aspirated and 
transferred to a tube containing 0.7% ammonium chloride 
solution and incubated at room temperature for 5 minutes to 
lyse any residual red blood cells. The cells were centrifuged 
at 450 rpm and 20°C for 10 minutes, the pellet was suspended 
in phosphate-buffered saline, and viability of the cells was 
determined using trypan blue exclusion staining. Further, 
cells were seeded at a density of 3.5 × 104/cm2 and cultured 
in Dulbecco’s Minimum Essential Medium-Low Glucose 
(DMEM-LG, Invitrogen, Bangalore, India) supplemented 
with 10% fetal bovine serum (Invitrogen) and 1% antibiotic-
antimycotic solution (Invitrogen) under standard culture 
conditions. The medium was changed once every 3 days 
until confluent (70%–80%) adherent cells were obtained. The 
primary hBMSC culture was subcultured for three passages 
with a change of medium twice a week. Further studies were 
carried out with the cells obtained after third passage.
Flow cytometric characterization  
of hBMscs
Approximately 1 × 106 cells were treated with fluorochrome-
tagged antibodies CD90-PERCP, CD44-FITC, CD29-PE, 
CD73-PE (BD Biosciences, Gurgoan, India), and CD105-
APC (e Biosciences, Santiago, CA, USA), positive markers 
for mesenchymal stem cells, CD34-PE (e Biosciences) and 
CD45-APC-Cy7 (e Biosciences), CD133-APC-A, CD31-
FITC, HLA-DR-PERCP (BD Biosciences, India)   negative 
markers. The cells were incubated with antibodies for 
20 minutes in the dark and washed three times with wash 
flow buffer (phosphate-buffered saline supplemented with 
2% [v/v] fetal bovine serum and 0.1% [w/v] sodium azide). 
Further, analyses were carried out using a FACSAria™ flow 
cytometer (BD Biosciences) and data acquisition was done 
using FACSDiva™ software (BD Biosciences).20
Multilineage differentiation  
potential of hBMscs
Cells with 70%–80% confluency were harvested with trypsin 
0.25%, and approximately 3 × 104 cells were cultured in 
DMEM-LG under standard conditions until 80%   confluency.20 
The subconfluent cells were treated with osteogenic medium 
(DMEM-LG containing 10% fetal bovine serum, 1% 
  antibiotic, 0.1 µM dexamethasone, Sigma-Aldrich, India), 
10 mM glycerophosphate (Sigma-Aldrich, India), and 
2 mM ascorbic acid (Sigma-Aldrich, India) and cultured for 
15 days. The culture was washed with phosphate-buffered 
saline (pH 7.4) and fixed with formalin (10%). von Kossa 
staining was performed to confirm calcium deposits. Silver 
nitrate 1% was added to the fixed cell culture and illuminated 
under ultraviolet light for 45 minutes. Sodium thiosulfate 5% 
was added, and the cell culture was then washed with distilled 
water for imaging under light microscopy.
Adipogenic differentiation was induced by addition of 
adipogenic medium to subconfluent culture.20 The adipogenic 
medium contained DMEM-LG, 10% fetal bovine serum, 
1% antibiotic-antimycotic solution, 0.1 µM dexamethasone 
(Sigma-Aldrich), 0.5 mM isobutyl methylxanthine (Sigma-
Aldrich), 1 µg insulin (Sigma-Aldrich), and 200 mM indo-
methacin (Sigma-Aldrich). Cells were cultured in adipogenic 
medium for 14 days and fixed with 10% formalin in saline. 
The fixed cells were washed with 60% isopropanol and 
stained with Oil Red O (Sigma-Aldrich) for 10 minutes. 
The stained cells were then washed and imaged under light 
microscopy.
hBMsc seeding on scaffolds
hBMSCs were seeded onto sterile 1.5 × 1.5 cm scaffolds.21 
Four different groups of scaffolds were seeded with cells at 
a density of 5 × 105 cells/mL and cultured under standard 
conditions. The groups were PCL-RNP, PCL-Res (10−6 M 
resveratrol added to medium), and PCL (positive control) 
cultured in osteogenic medium, and PCL (negative control) International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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cultured in DMEM-LG. The medium was supplemented 
with 10% fetal bovine serum and 1% antibiotic-antimycotic 
solution. After 6 hours of cell seeding, the scaffolds were 
transferred to fresh culture plates to negate the effect of cells 
voided from the scaffolds. The culture was carried out for 
16 days with a change of medium every 3 days.
MTT assay for cytotoxicity
The MTT (3(4,5dimethlythiazol-eyl) 2,5diphenly-tetrazoli-
umbromide, Sigma-Aldrich) assay was performed to evalu-
ate cell viability.21,22 First, 1 × 103 cells were seeded onto the 
scaffolds (in the groups described above) and cultured under 
standard conditions. On day 7, the scaffolds were washed with 
phosphate-buffered saline and 100 µL of MTT (5 mg/mL in 
sterile distilled water) was added and cultured for 10 hours. 
The formazan crystals formed were solubilized in dimethyl 
sulfoxide and read at 590 nm using an enzyme-linked immu-
nosorbent assay reader.
alkaline phosphatase assay
The cell-seeded scaffolds were washed with phosphate-buffered   
saline and alkaline phosphatase activity was assayed on days 
8 and 12 using 5-bromo-4-chloro-3-indolyl phosphate/nitro 
blue tetrazolium (BCIP-NBT, Sigma-Aldrich).21,22 BCIP-
NBT solution was prepared according to the manufacturer’s 
protocol. Next, 200 µL of BCIP-NBT was added to each 
scaffold and incubated for 2 hours. The violet crystals 
formed were solubilized with 300 µL of sodium dodecyl 
sulfate 10% HCl solution for 18 hours. Absorbance was 
measured using the enzyme-linked immunosorbent assay 
reader at 595 nm.
von Kossa staining of mineralized 
scaffolds
On day 16, the cell-seeded scaffolds were washed with 
phosphate-buffered saline (pH 7.4) and fixed in 10% neutral 
buffered formalin.20 The fixed scaffolds were cut horizontally 
with a uniform thickness of 10 µm. The slides were flooded 
with 1% silver nitrate solution and incubated under an ultra-
violet lamp for 45 minutes. Sodium thiosulfate 5% was added 
to stop the reaction, and the slides were thoroughly washed 
with tap water and imaged using light microscopy.
statistical analysis
The data were imported into GeneSpring GX7.3 microarray 
software (Agilent Technologies) in which analysis of vari-
ance was carried out to determine the significant difference 
(P # 0.05) between PCL-RNP and other groups on alkaline 
phosphatase and MTT assays.23 All tests were performed 
using three different patient samples (n = 3) in triplicate.
Results and discussion
Material characterization
scanning electron microscopy
Scanning electron microscopy of PCL-RNP showed highly 
interconnected porous structures with nanoparticles embed-
ded on the surface of the scaffolds (Figure 1). The nanopar-
ticles were uniformly spread throughout the surface, with few 
found to be agglomerated. The pore size of PCL-RNP was 
in the range of 50–150 µm. Pore size and interconnectivity 
is an important factor for penetration of cells into scaffolds. 
Previous studies have shown that scaffolds with a pore size 
greater than 100 µm are most suitable for cell penetration.24 
These observations suggest that these scaffolds are morpho-
logically suitable for cell penetration.
FTIr analysis
The scaffolds were analyzed by FTIR spectroscopy. The 
measured transmittance of PCL-RNP (Figure 2D) showed 
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Figure 1 scanning electron microscopy images of Pcl-rNP. (A) Pcl-rNP showing 
pores in the range of 50–100 µm. (B–D) Further magnification into the scaffold.   
(E and F) Nanoparticles and agglomerates embedded on the surface of the scaffold.
Note: green and yellow arrows show embedded nanoparticles and agglomerations, 
respectively. 
Abbreviations:  Pcl,  polycaprolactone;  rNP,  resveratrol-loaded  albumin 
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a strong band at 1,730 cm−1, corresponding to C=O stretch-
ing, and two bands at 2,949.18 cm−1 and 2,868.84 cm−1, 
representing symmetric and asymmetric CH2 bond stretch-
ing, respectively. These bands correspond to the aliphatic 
polyester PCL spectrum (Figure 2A).25 Further, bands 
for albumin were observed in the range of 4,000 cm−1 to 
1,500 cm−1.22 Absorption at 1,600 cm−1 to 1,450 cm−1 sug-
gested an aromatic ring, and a band near 3,400 cm−1 to 
3,300 cm−1 indicated an O-H group. A typical trans olefinic 
band was observed at 961.01 cm−1 (Figure 2B), which is a 
characteristic band for resveratrol.25 There was no change 
in the bands for resveratrol in PCL-RNP, indicating that 
no chemical bonding between resveratrol, albumin, and 
PCL had occurred during synthesis and processing of the 
  scaffolds. The RNP (Figure 2C) also showed the charac-
teristic bands of resveratrol and albumin at corresponding 
wavelengths, as discussed above. Hence, resveratrol was not 
modified on initial entrapment into albumin nanoparticles. 
Our results show that resveratrol was not chemically altered 
and hence increases the potential of PCL-RNP in releasing 
resveratrol at the therapeutic site.
X-ray diffraction analysis
X-ray diffraction analysis was carried out to determine the 
crystallinity of PCL-RNP. Two semicrystalline peaks at 
a 2θ value of 21.6 and 23.8 were obtained for PCL-RNP 
(Figure 3).25 Standard resveratrol showed peaks at 2θ values 
of 6.6, 16.4, 19.2, 22.4, 23.6, 25.3, and 28.4.25 However, 
no such peaks were seen for PCL-RNP and RNP, implying 
that resveratrol is amorphized during nanoencapsulation. 
The amorphization of resveratrol was due to loss of the 
structural arrangement of the lattice during its entrapment 
into RNP and consequently in PCL-RNP. The presence of 
resveratrol in PCL-RNP was confirmed by FTIR analysis 
and drug release studies. Hence, the absence of charac-
teristic peaks of resveratrol is due to its amorphization. 
A previous study of microencapsulation of resveratrol25 
also reported amorphization and its importance in drug 
targeting. Amorphization in the solid state increases dis-
solution of a drug, which is preferred in drug targeting 
especially when the drug is hydrophobic. These results 
suggest entrapment of resveratrol in nanoparticle form into 
a scaffold improves the dissolution of resveratrol which, in 
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Figure 2 Fourier transform infrared spectra. (A) Pcl spectra showing transmittance peaks for standard Pcl. (B) standard resveratrol spectra showing a typical trans 
olefinic band at 930–961 cm−1. (C) rNP spectra depicting albumin and characteristic resveratrol bands. (D) standard Pcl-rNP spectra show bands characteristic for Pcl 
(2,900–2,800 cm−1), resveratrol (930–961 cm−1), and albumin. 
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turn, increases the drug delivery potential of PCL-RNP in 
bone tissue engineering.
characterization of rNPs
The size of the RNP was determined using atomic force 
microscopy, scanning electron microscopy, and a zetasizer. 
Atomic force microscopy showed the mean size of the RNP 
to be 172 nm. Similarly, scanning electron microscopy of the 
nanoparticles suggested the particle size to be in the range of 
90–190 nm (Figure 4). Further, the polydispersibility index, 
zeta potential, and average size of the RNP was recorded by 
zetasizer to be 0.035, −27.5 mV , and 133 nm, respectively. 
The zeta potential and polydispersibility index indicate that 
the particles did not undergo agglomeration. Finally, the 
drug loading efficiency, calculated from the free drug in the 
supernatant, was found to be 55%. These results confirm that 
the particle size of RNP is well within that nanometer range, 
and that they are highly stable and potent drug carriers.
analysis of resveratrol release  
from Pcl-rNP
The release of resveratrol from PCL-RNP did not show a 
burst effect as compared with RNP, which showed a burst 
effect at 6 hours (Figure 5). Sustained release of resveratrol 
from PCL-RNP was observed until 12 days, with the total 
amount of resveratrol released at the end of 12 days being 
64%, whereas RNP showed release of more than 80% in 
6 days and a cumulative release of 90% at the end of 12 days. 
This sustained release of resveratrol from PCL-RNP is 
attributed to the entrapment of RNP into PCL, which acts 
as a barrier for the release of resveratrol from nanoparticles. 
These results confirm that entrapment of RNP into PCL scaf-
folds delayed the release of resveratrol, which is desirable 
for therapeutic scaffolds.
characterization of hBMscs
At third passage, the percentages of cells expressing CD90, 
CD105, CD73, CD44, and CD29 (positive markers for mes-
enchymal stem cells) were 99.4, 99.7, 99.2, 98.8, and 99.1, 
respectively (Figure 6-I). The percentages of cells expressing 
CD34, CD45, CD133, CD31, and HLA-DR (negative mark-
ers for mesenchymal stem cells) were found to be 5.7, 3.4, 
3.4, 0.8, and 17 respectively (Figure 6-II). The percentage 
of contaminating hematopoietic lineages was negligible; 
further, the cells were adherent and maintained a flattened 
elongated shape throughout the passages (Figure 7). These 
results suggest that the cells harvested at third passage were 
mesenchymal. The plasticity of the adherent mesenchymal 
stem cells was confirmed by osteogenic and adipogenic dif-
ferentiation (Figure 7). Confirmation of osteogenic differen-
tiation was done by staining calcium deposits with von Kossa 
stain which turned calcium black by day 21.   Adipogenic 
differentiation was confirmed by Oil Red O staining (which 
stains lipid vacuoles red) on day 18. Mesenchymal stem cells 
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cultured in noninductive medium (DMEM-LG) served as the 
control for staining.
MTT and alkaline phosphatase assays
The MTT assay (Figure 8) showed that the scaffolds were not 
cytotoxic. A significant (P # 0.01) increase in activity was 
observed in PCL-RNP and PCL-Res compared with PCL 
(the positive control). This is due to the proliferative effect 
of resveratrol on hBMSCs. A previous study also reported 
a dose-dependent proliferative effect of resveratrol.12 In 
addition, the BCIP-NBT assay showed that alkaline phos-
phatase activity was significantly increased in PCL-RNP 
(Figure 9) compared with the positive control by 1.62-fold 
(P # 0.001) and 1.42-fold (P # 0.001) on day 8 and day 
12, respectively. PCL-Res showed a significant increase of 
1.6-fold (P # 0.001) and 1.4-fold (P # 0.001) on day 8 and 
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Figure 6 Immunophenotyping of cell surface markers of hBMSCs using flow cytometric analysis. (I) Positive markers for mesenchymal stem cells: (A) cD90-PercP,   
(B) cD105-aPc, (C) cD73-Pe, (D) cD44-FITc, (E) cD29-Pe, showing higher percentage expression (control and sample as labeled). (II) Negative markers for mesenchymal 
stem cells: (A) cD34-Pe, (B) cD45-aPc-cy7, (C) cD133-aPc-a, (D) cD31-FITc, (E) hla-Dr-PercP show a low percentage expression (control and sample as labeled).
Note: The surface marker profile shows that the cells obtained at third passage were mesenchymal stem cells. BM1-P3-DMEM-LG represents bone marrow cells obtained 
at third passage in DMeM-lg medium. 
Abbreviations: DMeM-lg, Dulbecco’s Minimum essential Medium-low glucose; hBMscs, human bone marrow-derived mesenchymal stem cells; ssc, side scatter; BM, 
bone marrow.
day 12, respectively, compared with the positive control. 
The results obtained imply that PCL-RNP was as potent 
as PCL-Res in inducing alkaline phosphatase activity. 
A previous study observed increased alkaline phosphatase 
activity over a wide range of concentrations (10−6 to 10−5 M) 
of resveratrol.12–15 Hence, for a scaffold to be bioactive, the 
concentration of resveratrol release needs to be in the range 
of 10−11 M to 5 µM.12 Alkaline phosphatase is a key early 
marker in bone formation and differentiation of mesenchymal 
stem cells into an osteoblastic lineage. Hence, the increase in International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 7 characterization of hBMscs at third passage. (A) Morphology of cells on 
day 7 of culture. (B) Morphology of hBMSCs on day 14, showing 80% confluency. 
(C) von Kossa staining for calcium deposits shown as black-colored crystals after 
osteogenic  differentiation  and  (D)  Oil  O  red  stains  of  lipids  after  adipogenic 
differentiation.
Note: all images were obtained under light microscopy at 100× magnification. 
Abbreviation: hBMscs, human bone marrow-derived mesenchymal stem cells.
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Figure  8  MTT  assay  on  day  7  of  cell  seeding  on  scaffolds  shows  significantly 
increased activity of cells in Pcl-rNP (P # 0.01) and Pcl-res (P # 0.01) compared 
with the positive and negative Pcl controls. 
Abbreviations: Pcl, polycaprolactone; rNP, resveratrol-loaded albumin nanoparticles; 
res, resveratrol.
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Figure 9 alkaline phosphatase assay showing fold increase against Pcl (positive 
control) activity taken as 100%. (A) alkaline phosphatase assayed on day 8 shows 
significantly increased activity in PCL-RNP (P # 0.001) and Pcl-res (P # 0.001) 
compared with Pcl (positive control) and (B) on day 12 of culture on scaffolds 
shows  significantly  increased  activity  in  PCL-RNP  (P  #  0.001)  and  Pcl-res 
(P # 0.001) compared with Pcl (positive control).
Note: Positive control, cell culture done on Pcl scaffold in osteogenic medium; 
negative control, cell culture done on Pcl scaffold in DMeM-lg medium. 
Abbreviations:  Pcl,  polycaprolactone;  rNP,  resveratrol-loaded  albumin 
nanoparticles; res, resveratrol; DMeM-lg, Dulbecco’s Minimum essential Medium-
low glucose.
alkaline phosphatase activity induced by PCL-RNP confirms 
that release of resveratrol is within the desired range, which 
further suggests that PCL-RNP is osteoinductive.
von Kossa staining of mineralized 
scaffolds
Calcium deposits in PCL-RNP, PCL-Res, and PCL (posi-
tive control) were compared and determined by von Kossa 
staining. The results showed increased calcium deposition 
in PCL-RNP and PCL-Res compared with the positive con-
trol (Figure 10). Further, the calcium deposits were present 
uniformly throughout the sections of PCL-RNP, PCL-Res, 
and the positive control. These results indicate the mineral-
izing and osteogenic properties of PCL-RNP. A previous 
report also suggested increased mineralization in nanofibers 
Figure 10 von Kossa stained scaffolds showing calcium deposits as black-colored 
patches with 250× magnification. (A) Pcl (positive control), (B) Pcl (negative 
control), (C) Pcl-rNP, and (D) Pcl-res.
Note: Positive control, cell culture done on Pcl scaffold in osteogenic medium; 
negative control, cell culture done on Pcl scaffold in DMeM-lg medium. 
Abbreviations:  Pcl,  polycaprolactone;  rNP,  resveratrol-loaded  albumin 
nanoparticles; res, resveratrol; DMeM-lg, Dulbecco’s Minimum essential Medium-
low glucose.International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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  releasing   resveratrol.12 However, this is the first report of 
sustained release of resveratrol from three-dimensional 
porous solid scaffolds. PCL-RNP could also be synthesized 
and fabricated into desired   dimensions. The therapeutic 
potential, straightforward synthesis, and fabrication process 
for PCL-RNP is highly prognostic for its use in grafts for 
fractures with large bone loss.
Conclusion
In this study, resveratrol was released from scaffolds in a 
sustained manner. Resveratrol was also amorphized due to its 
entrapment in nanoparticles, which increased the dissolution 
of resveratrol. Drug release from PCL-RNP was sustained for 
12 days, with a total release of 64%. PCL-RNP was potent in 
increasing proliferation, induction of alkaline phosphatase, 
and mineralization. This study emphasizes the use of bioactive 
small molecules obtained from plant sources for targeting in 
bone tissue engineering. Prolonged release of these bioactive 
molecules can potentially overcome the adverse effects elicited 
by therapeutic delivery of certain indigenous growth factors. To 
conclude, prolonged release of resveratrol from PCL-RNP is 
highly desirable in bone tissue engineering because it is osteo-
conductive and osteoinductive, and promotes osteogenesis.
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